Aaron Deykin's most recent trade in Upstream Bio Inc. was a trade of 895 Common Stock done at an average price of $5.5 . Disclosure was reported to the exchange on Sept. 16, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Upstream Bio Inc | Aaron Deykin | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.49 per share. | 16 Sep 2026 | 895 | 32,302 | - | 5.5 | 4,914 | Common Stock |
| Upstream Bio Inc | Aaron Deykin | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 6.10 per share. | 16 Jun 2026 | 895 | 33,197 | - | 6.1 | 5,460 | Common Stock |
| Upstream Bio Inc | Aaron Deykin | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 9.29 per share. | 16 Mar 2026 | 894 | 32,687 | - | 9.3 | 8,305 | Common Stock |
| Upstream Bio Inc | Aaron Deykin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 96,000 | 96,000 | - | - | Stock Option (Right to Buy) | |
| Upstream Bio Inc | Aaron Deykin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 32,000 | 33,581 | - | 0 | Common Stock | |
| Upstream Bio Inc | Aaron Deykin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 165,000 | 165,000 | - | - | Stock Option (Right to Buy) |